11. SEPT. 2020

boehringer-ingelheim.com › press-release › phase-ii-results-cognitive

The Phase II results of BI 425809 in cognitive impairment associated with schizophrenia are being further evaluated to assess how they will support the continued research development for the treatment…

boehringer-ingelheim.com › de › psychische-erkrankungen › schizophrenie

Boehringer Ingelheim hat das Ziel, die Gesundheit von Mensch und Tier zu verbessern. Als global agierendes, familiengeführtes Unternehmen planen wir in Generationen. OUR FOCUS beschreibt wer wir sind, was uns…

1. NOV. 2021

boehringer-ingelheim.com › human-health › mental-disorders › schizophrenia

Schizophrenia is characterized by three symptom domains and affects ~1% of global population. First and mostly known are the positive symptoms like hallucinations and delusions, secondly are negative symptoms like …

24. MAI 2021

boehringer-ingelheim.com › press-release › btd-glyt1-schizophrenia

Ingelheim, 25 May 2021 – Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of…

11. SEPT. 2020

boehringer-ingelheim.com › press-release › partnership-clicktherapeutics

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia. Ingelheim, Germany and New York,…

5. APR. 2022

handelsblatt.com › technik › thespark › pharmakonzern-neue-mittel-gegen

Pharmakonzern Neue Mittel gegen Herzschwäche, Krebs, Schizophrenie: So will Boehringer die nächste Wachstumsphase starten. Neue Mittel gegen Herzschwäche, Krebs, Schizophrenie: So will ...

21. MAI 2021

boehringer-ingelheim.com › us › press-release › boehringer-ingelheims

RIDGEFIELD, CT, May 24, 2021 – Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment…

6. DEZ. 2019

boehringer-ingelheim.com › central-nervous-system › prevention-schizophrenia

BI is currently conducting a large multinational phase II study in persons with Attenuated Psychosis Syndrome (people at high risk for the development of schizophrenia) to see if the drug…

pubmed.ncbi.nlm.nih.gov › 33610228

Background: Cognitive impairment associated with schizophrenia predicts poor functional outcomes, but currently no approved pharmacotherapy is available. This study investigated whether the glycine transporter-1 inhibitor BI 425809 improves cognition in…

7. SEPT. 2022

pro.boehringer-ingelheim.com › events › cns-congresses › ecnp-focus-on-schizophrenia

Our approach to Cognitive Impairment Associated with Schizophrenia (CIAS) Hear about the impact of CIAS and why Boehringer Ingelheim is focusing on this to push the boundaries of mental health…

nature.com › articles › d43747-021-00069-z

Recognizing the potential to improve the treatment of diseases including schizophrenia, depression and impulsivity disorders, Boehringer Ingelheim is seeking opportunities to use its discovery and ...